Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
Public ClinicalTrials.gov record NCT02097849. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label Study to Assess the Immune Response to Vaccination in Tecfidera® (BG00012)-Treated Versus Interferon-Treated Subjects With Relapsing Forms of Multiple Sclerosis.
Study identification
- NCT ID
- NCT02097849
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Biogen
- Industry
- Enrollment
- 71 participants
Conditions and interventions
Conditions
Interventions
- dimethyl fumarate Drug
- tetanus diphtheria toxoids vaccine Biological
- 23-valent pneumococcal polysaccharide vaccine Biological
- meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent) Biological
- non-pegylated interferon Drug
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2015
- Primary completion
- May 1, 2016
- Completion
- May 1, 2016
- Last update posted
- Jun 1, 2017
2015 – 2016
United States locations
- U.S. sites
- 14
- U.S. states
- 10
- U.S. cities
- 14
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Gilbert | Arizona | 85234 | — |
| Research Site | Thornton | Colorado | 80233 | — |
| Research Site | Fort Lauderdale | Florida | 33312 | — |
| Research Site | Sarasota | Florida | 34243 | — |
| Research Site | Indianapolis | Indiana | 46202 | — |
| Research Site | Lexington | Kentucky | 40513 | — |
| Research Site | Auburn | Maine | 04210 | — |
| Research Site | New York | New York | 10016 | — |
| Research Site | Charlotte | North Carolina | 28203 | — |
| Research Site | Akron | Ohio | 44320 | — |
| Research Site | Cleveland | Ohio | 44195 | — |
| Research Site | Dayton | Ohio | 45417 | — |
| Research Site | Round Rock | Texas | 78761 | — |
| Research Site | San Antonio | Texas | 78258 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02097849, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 1, 2017 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02097849 live on ClinicalTrials.gov.